TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Relmada Therapeutics ( (RLMD) ) is now available.
Relmada Therapeutics reported its third-quarter 2025 financial results and provided updates on its NDV-01 program for non-muscle invasive bladder cancer (NMIBC). The company announced positive 9-month follow-up data for NDV-01, showing a 92% complete response rate, and secured FDA alignment on key elements of its Phase 3 program. Additionally, Relmada completed a $100 million underwritten offering to support its operations into 2028, which will help advance the NDV-01 registrational studies and the development of sepranolone for Prader-Willi Syndrome.
The most recent analyst rating on (RLMD) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Relmada Therapeutics stock, see the RLMD Stock Forecast page.
Spark’s Take on RLMD Stock
According to Spark, TipRanks’ AI Analyst, RLMD is a Neutral.
Relmada Therapeutics’ overall score reflects its high-risk, high-reward profile typical of biotechnology firms in developmental stages. The company’s financial performance is weakened by zero revenue and significant cash burn, tempered by strong cash reserves. Strategic pipeline developments and recent acquisitions offer potential upside, but are countered by challenges such as discontinued projects and reliance on external financing. Technical analysis shows short-term momentum, but the overall outlook remains speculative.
To see Spark’s full report on RLMD stock, click here.
More about Relmada Therapeutics
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for oncology and central nervous system indications.
Average Trading Volume: 1,195,702
Technical Sentiment Signal: Hold
Current Market Cap: $129.8M
See more insights into RLMD stock on TipRanks’ Stock Analysis page.